RHJA
URGN icon

Rice Hall James & Associates’s UroGen Pharma URGN Stock Holding History

Rice Hall James & Associates’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.1M Buy
300,650
+14,816
+5% +$402K 0.54% 58
2026
Q1 		$5.14M Buy
285,834
+3,958
+1% +$79.4K 0.29% 83
2025
Q4 		$6.6M Buy
281,876
+22,733
+9% +$493K 0.36% 68
2025
Q3 		$5.17M Sell
259,143
-28,731
-10% -$516K 0.28% 84
2025
Q2 		$3.94M Buy
287,874
+32,083
+13% +$308K 0.21% 100
2025
Q1 		$2.83M Sell
255,791
-8,240
-3% -$87.9K 0.17% 130
2024
Q4 		$2.81M Sell
264,031
-7,866
-3% -$94.2K 0.15% 145
2024
Q3 		$3.45M Buy
271,897
+199,110
+274% +$2.96M 0.19% 123
2024
Q2 		$1.22M Buy
72,787
+2,381
+3% +$33.9K 0.07% 197
2024
Q1 		$1.06M Buy
70,406
+514
+0.7% +$8.4K 0.06% 208
2023
Q4 		$1.05M Sell
69,892
-5,288
-7% -$68.6K 0.06% 214
2023
Q3 		$1.05M Sell
75,180
-907
-1% -$14.6K 0.07% 202
2023
Q2 		$788K Buy
76,087
+2,882
+4% +$31.8K 0.04% 230
2023
Q1 		$676K Buy
73,205
+274
+0.4% +$2.52K 0.04% 240
2022
Q4 		$647K Sell
72,931
-1,500
-2% -$14.2K 0.04% 242
2022
Q3 		$619K Sell
74,431
-36,026
-33% -$298K 0.04% 242
2022
Q2 		$905K Buy
110,457
+2,467
+2% +$16.9K 0.04% 231
2022
Q1 		$941K Buy
107,990
+6,631
+7% +$51.7K 0.04% 242
2021
Q4 		$964K Sell
101,359
-47,901
-32% -$675K 0.03% 246
2021
Q3 		$2.51M Sell
149,260
-92,377
-38% -$1.46M 0.09% 170
2021
Q2 		$3.69M Sell
241,637
-45,168
-16% -$817K 0.13% 119
2021
Q1 		$5.59M Buy
286,805
+184,752
+181% +$3.92M 0.18% 101
2020
Q4 		$1.84M Buy
+102,053
New +$2.14M 0.06% 208

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Rice Hall James & Associates's URGN Position: Q2 2026 in Review

Rice Hall James & Associates increased its UroGen Pharma (URGN) stake by 5.2% in Q2 2026, buying an estimated $402K and bringing the position to 300,650 shares worth $11.1M. The position accounts for 0.54% of the portfolio, ranked #58.

Rice Hall James & Associates first reported a position in URGN in Q4 2020 and has held it in 23 quarters since. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • Rice Hall James & Associates held 300,650 shares of UroGen Pharma worth $11.1M as of Q2 2026.
  • Rice Hall James & Associates bought 14,816 UroGen Pharma shares in Q2 2026, an estimated $402K.
  • UroGen Pharma made up 0.54% of Rice Hall James & Associates's portfolio in Q2 2026, its #58 holding.
  • Rice Hall James & Associates first reported a position in UroGen Pharma in Q4 2020 and has held it in 23 quarters since.
  • 189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Rice Hall James & Associates's 13F filing for Q2 2026, filed 7 Aug 2026.